XWXing Wei

Xing Wei

*This is an algorithmically generated author record based on publicly available information.

Xing Wei has a total of 108 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Discovery of RMC-0708, an Oral, Bis-Macrocyclic, RAS(ON) Q61H-Selective, Noncovalent, Tri-Complex Inhibitor

    by Severin K. Thompson, Yu C. Yang, Antonio J. LópEz QuiñoNes, Stephanie Chang, Jessica L. McKinley, Aidan C. A. Tomlinson, Aaron Seth Tooley, Xing Wei, Michael Flagella, Andreas Buckl, et al.

    Oncogenic RAS mutations are among the most common drivers of human cancers, with the KRAS Q61H mutation accounting for approximately 7500 new patients each year in the US alone. To target the active, GTP-bound state of the KRAS(ON) Q61H mutant protein directly, we have employed an innovative tri-complex inhibitor (TCI) modality. Herein, we report structure-guided medicinal chemistry efforts that led to the discovery of RMC-0708, an orally bioavailable, bis-macrocyclic, RAS(ON) Q61H-selective, noncovalent, tri-complex inhibitor. Oral administration of a single dose of RMC-0708 resulted in dose-dependent, deep, and durable suppression of tumor RAS pathway activity for up to 72 h in preclinical xenograft models of KRAS Q61H-driven cancers in vivo. RMC-0708 drove deep tumor regressions in several xenograft models of human KRAS Q61H mutant tumors. The discovery of RMC-0708 further underscores the potential of the TCI platform to identify potent and selective noncovalent inhibitors of mutant RAS(ON) with demonstrated selectivity over wild-type RAS.

  • Open Access

    Supplementary Figures S1-S7 from Abrogation of Oncogenic RAS Signaling by a RAS(ON) Inhibitor Doublet Primes Immune-Refractory KRASG12C-Mutant NSCLC for Immune Checkpoint Blockade

    by Xing Wei, Cristina Blaj, M. Ali Al-Radhawi, Lick Pui Lai, Benjamin J. Maldonato, Yu Chi Yang, Lillian Seu, Harika Gundlapalli, Lingyan Jiang, Mariela A. Moreno Ayala, et al.

    Supplementary Figure 1. The RAS(ON) inhibitor doublet induces deep and durable responses in KRASG12C-mutant NSCLC models and is tolerated based on animal body weight assessment. Supplementary Figure 2. The RAS(ON) inhibitor doublet demonstrates combinatorial benefit in vitro. Supplementary Figure 3. The RAS(ON) inhibitor doublet demonstrates combinatorial benefit in vivo. Supplementary Figure 4. Graphical representation of the combined PK/TE/PD model. Supplementary Figure 5. Elironrasib and daraxonrasib synergize and drive ICD and immune dependent CR in the KPAR1.3 model. Supplementary Figure 6. The RAS(ON) doublet increases depth of response in the 3LL-ΔNRAS model. Supplementary Figure 7. Immuno-sequencing (TCRB assay) of gDNA extracted from 3LL-ΔNRAS tumors collected at 24 hours post 8 days of daily oral treatment with vehicle, elironrasib at 30 mg/kg or daraxonrasib at 25 mg/kg or the RAS(ON) doublet.

  • Open Access

    Figure 3 from Abrogation of Oncogenic RAS Signaling by a RAS(ON) Inhibitor Doublet Primes Immune-Refractory KRASG12C-Mutant NSCLC for Immune Checkpoint Blockade

    by Xing Wei, Cristina Blaj, M. Ali Al-Radhawi, Lick Pui Lai, Benjamin J. Maldonato, Yu Chi Yang, Lillian Seu, Harika Gundlapalli, Lingyan Jiang, Mariela A. Moreno Ayala, et al.

    RAS(ON) inhibitor doublet drives sustained RAS signaling suppression, inhibits cell proliferation, and induces apoptosis in vivo. A, Target engagement of KRASG12C protein by elironrasib in NCI-H2122 (KRASG12C/G12CSTK11mutKEAP1mut, NSCLC) subcutaneous xenograft tumors, shown as the percentage of cross-linked KRASG12C by elironrasib relative to controls. Tumor-bearing mice were treated with 17 consecutive daily doses of elironrasib at 100 mg/kg as single agent (blue line) or in combination with daraxonrasib at 25 mg/kg (purple line). Tumors were harvested at indicated time points (n = 2–3 per time point). Values are plotted as mean ± SEM. B, PD in NCI-H2122 (KRASG12C/G12CSTK11mutKEAP1mut, NSCLC) subcutaneous xenograft tumors, shown as the relative change in human DUSP6 mRNA expression. Tumor-bearing mice were treated with a single dose (every day ×1, solid lines) or seven consecutive daily doses (every day ×7, dashed lines) of elironrasib at 100 mg/kg and daraxonrasib at 25 mg/kg as single agents or in combination. Tumors were harvested at indicated time points (n = 2–3 per time point). Data from elironrasib single agent, daraxonrasib single agent, and RAS(ON) inhibitor doublet groups are plotted in blue lines, green lines, and purple lines, respectively. Values are plotted as mean ± SEM. C and D, Histopathology analysis of NCI-H2122 subcutaneous xenograft tumors treated with a single dose (every day ×1, circles in the quantification plot) or seven consecutive daily doses (every day ×7, dots in the quantification plot) of elironrasib at 100 mg/kg and daraxonrasib at 25 mg/kg as single agents or in combination and collected at indicated time points (n = 3 per time point). C, Representative images are shown at 20× magnification from samples closest to the mean of the group. Tumors used for representative images of pERK, pS6, and Ki67 were collected at 48 hours after seven consecutive daily doses of RAS(ON) inhibitors. Tumors used for representative images of CC3 were collected at 24 hours after a single dose of RAS(ON) inhibitors. Scale bars, 100 μm. D, pERK, pS6, and CC3 staining in tumor areas and Ki67 staining in tumor cell nucleuses were quantified and compared with vehicle using one-way ANOVA followed by Dunnett multiple comparison test (*, P < 0.05; **, P < 0.01; ***, P < 0.001; ****, P < 0.0001). E, PD in CTG-2536 (KRASG12C/WT, HER2High, NSCLC) subcutaneous PDX tumors, shown as the relative change in human DUSP6 mRNA expression. Tumor-bearing mice were treated with a single dose of elironrasib at 200 mg/kg and daraxonrasib at 25 mg/kg as single agents or in combination. Tumors were harvested at indicated time points (n = 2–3 per time point). Data from elironrasib single agent, daraxonrasib single agent, and RAS(ON) inhibitor doublet groups are plotted in blue lines, green lines, and purple lines, respectively. Values are plotted as mean ± SEM. F, Histopathology analysis of CTG-2536 subcutaneous PDX tumors treated with a single dose of elironrasib at 200 mg/kg and daraxonrasib at 25 mg/kg as single agents or in combination and collected at indicated time points (n = 3 per time point). Representative images are shown at 20× magnification from samples closest to the mean of the group. Tumors used for representative images of pERK and CC3 were collected at 48 and 24 hours after a single dose of RAS(ON) inhibitors, respectively. Scale bars, 100 μm. po, orally; qd, every day.

  • Open Access

    Figure 2 from Abrogation of Oncogenic RAS Signaling by a RAS(ON) Inhibitor Doublet Primes Immune-Refractory KRASG12C-Mutant NSCLC for Immune Checkpoint Blockade

    by Xing Wei, Cristina Blaj, M. Ali Al-Radhawi, Lick Pui Lai, Benjamin J. Maldonato, Yu Chi Yang, Lillian Seu, Harika Gundlapalli, Lingyan Jiang, Mariela A. Moreno Ayala, et al.

    RAS(ON) inhibitor doublet forestalls resistance driven by elevated RAS pathway flux. A, Antitumor activity of elironrasib and daraxonrasib as single agents or in combination in the NCI-H2122 (KRASG12C/G12CSTK11mutKEAP1mut, NSCLC) subcutaneous xenograft model (n = 8–15 per group). Tumor-bearing mice were treated with vehicle or RAS(ON) inhibitors (elironrasib at 100 mg/kg orally every day and daraxonrasib at 25 mg/kg orally every day as single agents or in combination) for 17 to 56 days. Mean tumor volumes of each group were plotted over the course of treatment. Vehicle control and specific treatment groups were compared by two-way repeated-measures ANOVA on the last measurement day of the vehicle group (***, P < 0.001; ****, P < 0.0001). The dotted line indicates the initial average tumor volume. Error bars, SEM. B, Antitumor activity of elironrasib and daraxonrasib as single agents or in combination in NCI-H2030 (KRASG12C/G12CSTK11mutKEAP1mut, NSCLC) subcutaneous xenograft model (n = 8 per group). Tumor-bearing mice were treated with vehicle or RAS(ON) inhibitors (elironrasib at 100 mg/kg orally every day and daraxonrasib at 25 mg/kg orally every day as single agents or in combination) for 21–89 days. Mean tumor volumes of each group were plotted over the course of treatment. Vehicle control and specific treatment groups were compared by two-way repeated-measures ANOVA on the last measurement day of the vehicle group (****, P < 0.0001). The dotted line indicates the initial average tumor volume. Error bars, SEM. C, Histopathology analysis of HER2 in eight KRASG12C-mutant NSCLC subcutaneous xenograft tumors at baseline included in the tumor response waterfall plot and Kaplan–Meier analysis in Fig. 1. Representative images are shown at 60× magnification. Scale bars, 50 μm. D, Antitumor activity of elironrasib, daraxonrasib, and elironrasib plus daraxonrasib combination in CTG-2536 (KRASG12C/WT, HER2High, NSCLC) subcutaneous PDX model (n = 4–6 per group). Tumor-bearing mice were treated with vehicle or RAS(ON) inhibitors (elironrasib at 200 mg/kg orally every day, daraxonrasib at 25 mg/kg orally every day, and combination of elironrasib at 200 mg/kg orally every day plus daraxonrasib at 25 mg/kg orally every day) for 16–90 days. Mean tumor volumes of each group were plotted over the course of treatment. Vehicle control and specific treatment groups were compared by two-way repeated-measures ANOVA on the last measurement day of the vehicle group, and none of the comparisons were statistically significant. The dotted line indicates the initial average tumor volume. Error bars, SEM. E, Antitumor activity of elironrasib, daraxonrasib, and elironrasib plus daraxonrasib combination in the LUN055 (KRASG12C Amp, NSCLC) subcutaneous PDX model (n = 3 per group). Tumor-bearing mice were treated with vehicle or RAS(ON) inhibitors (elironrasib at 100 mg/kg orally every day, daraxonrasib at 25 mg/kg orally every day and combination of elironrasib at 30 mg/kg orally every day plus daraxonrasib at 25 mg/kg orally every day) for 21–91 days. Mean tumor volumes of each group were plotted over the course of treatment. Vehicle control and specific treatment groups were compared by two-way repeated-measures ANOVA on the last measurement day of the vehicle group (*, P < 0.05). The dotted line indicates the initial average tumor volume. Error bars, SEM. Two tumor volume plots were from two different studies. F, Relative copy numbers of KRASWT or KRASG12C in LUN055 (KRASG12C Amp, NSCLC) subcutaneous PDX tumors (n = 2–3 per group) collected at the end of tumor growth studies as shown in E. Tumors used for ddPCR analysis were collected at 3 hours after the last dose of vehicle or inhibitors. The relative gene copy numbers were determined by ddPCR and normalized to RPP30. Specific treatment group was compared with vehicle control using one-way ANOVA followed by Dunnett multiple comparison test (*, P < 0.05; **, P < 0.01). G, DNA FISH, RNA ISH, and histopathology analysis of LUN055 (KRASG12C Amp, NSCLC) subcutaneous PDX tumors collected at the end of tumor growth studies as shown in E. Representative images are shown at 63×, 40×, and 40× magnification from ROIs closest to the mean of the group for FISH, RNA ISH, and IHC, respectively. Tumors used for representative images were collected at 3 hours after the last dose of vehicle or elironrasib. Scale bars, 50 μm. Cen12, centromere 12; ROI, region of interest; po, orally; qd, every day.

  • Open Access

    Table S8 from Abrogation of Oncogenic RAS Signaling by a RAS(ON) Inhibitor Doublet Primes Immune-Refractory KRASG12C-Mutant NSCLC for Immune Checkpoint Blockade

    by Xing Wei, Cristina Blaj, M. Ali Al-Radhawi, Lick Pui Lai, Benjamin J. Maldonato, Yu Chi Yang, Lillian Seu, Harika Gundlapalli, Lingyan Jiang, Mariela A. Moreno Ayala, et al.

    Table S8 from Abrogation of Oncogenic RAS Signaling by a RAS(ON) Inhibitor Doublet Primes Immune-Refractory KRASG12C-Mutant NSCLC for Immune Checkpoint Blockade

  • Open Access

    Table S2 from Abrogation of Oncogenic RAS Signaling by a RAS(ON) Inhibitor Doublet Primes Immune-Refractory KRASG12C-Mutant NSCLC for Immune Checkpoint Blockade

    by Xing Wei, Cristina Blaj, M. Ali Al-Radhawi, Lick Pui Lai, Benjamin J. Maldonato, Yu Chi Yang, Lillian Seu, Harika Gundlapalli, Lingyan Jiang, Mariela A. Moreno Ayala, et al.

    Table S2 from Abrogation of Oncogenic RAS Signaling by a RAS(ON) Inhibitor Doublet Primes Immune-Refractory KRASG12C-Mutant NSCLC for Immune Checkpoint Blockade

  • Open Access

    Table S7 from Abrogation of Oncogenic RAS Signaling by a RAS(ON) Inhibitor Doublet Primes Immune-Refractory KRASG12C-Mutant NSCLC for Immune Checkpoint Blockade

    by Xing Wei, Cristina Blaj, M. Ali Al-Radhawi, Lick Pui Lai, Benjamin J. Maldonato, Yu Chi Yang, Lillian Seu, Harika Gundlapalli, Lingyan Jiang, Mariela A. Moreno Ayala, et al.

    Primary antibody list for IHC staining

  • Open Access

    Table S3 from Abrogation of Oncogenic RAS Signaling by a RAS(ON) Inhibitor Doublet Primes Immune-Refractory KRASG12C-Mutant NSCLC for Immune Checkpoint Blockade

    by Xing Wei, Cristina Blaj, M. Ali Al-Radhawi, Lick Pui Lai, Benjamin J. Maldonato, Yu Chi Yang, Lillian Seu, Harika Gundlapalli, Lingyan Jiang, Mariela A. Moreno Ayala, et al.

    IHC staining quantification in xenograft tumors

  • Open Access

    Figure 5 from Abrogation of Oncogenic RAS Signaling by a RAS(ON) Inhibitor Doublet Primes Immune-Refractory KRASG12C-Mutant NSCLC for Immune Checkpoint Blockade

    by Xing Wei, Cristina Blaj, M. Ali Al-Radhawi, Lick Pui Lai, Benjamin J. Maldonato, Yu Chi Yang, Lillian Seu, Harika Gundlapalli, Lingyan Jiang, Mariela A. Moreno Ayala, et al.

    Elironrasib and daraxonrasib drive immune-dependent CRs, favorably modulate the TME, and synergize with anti–PD-1 in the immunogenic KPAR1.3 model. A, Tumor growth of subcutaneous tumors treated for 32 days (dashed line indicated treatment stop) with vehicle, elironrasib at 100 mg/kg, daraxonrasib at 25 mg/kg orally every day in combination with mouse IgG2a (isotype control), or anti–PD-1 at 10 mg/kg intraperitoneally twice a week in C57BL/6 mice shown as individual tumor volume (n = 10). Number of CRs indicated. B, Representative lung IHC images (large image – scale bar, 500 μm; zoomed in image – scale bar, 100 μm; # denotes enlarged area; dashed lines highlight large tumor nodules), percentage tumor area per lung area at 4 hours after 4 days of treatment with elironrasib at 30 mg/kg or daraxonrasib at 25 mg/kg orally every day (four lung sections were evaluated for each mouse) and quantification of CD8+ or CD4+ T cells as percentage of all cells within the tumor region in orthotopic lung tumors. Each point is the analysis of the tumor mass/section of lung. Four lung sections were evaluated for each mouse. Asterisks indicate analysis was performed using one-way ANOVA. For all statistical analysis ***, P < 0.001; ****, P < 0.0001. C, Tumor growth of subcutaneous tumors treated for 32 days (dashed line indicated treatment stop) with elironrasib at 100 mg/kg in combination with daraxonrasib at 25 mg/kg orally every day and mouse IgG2a (isotype control) or anti–PD-1 at 10 mg/kg intraperitoneally twice a week in C57BL/6 mice shown as individual tumor volume (n = 10). D, Tumor growth of subcutaneous tumors treated for 32 days with elironrasib at 100 mg/kg or daraxonrasib at 25 mg/kg orally every day in the presence of CD4 and CD8 T cell–depleting and NK cell–depleting antibodies administered at 10 mg/kg at day -1, 0, and every 6 days after dosing start. CRs are defined as tumor volume at 0 mm3. po, orally; qd, every day; biw, twice a week.

  • Open Access

    Supplementary Methods 1 from Abrogation of Oncogenic RAS Signaling by a RAS(ON) Inhibitor Doublet Primes Immune-Refractory KRASG12C-Mutant NSCLC for Immune Checkpoint Blockade

    by Xing Wei, Cristina Blaj, M. Ali Al-Radhawi, Lick Pui Lai, Benjamin J. Maldonato, Yu Chi Yang, Lillian Seu, Harika Gundlapalli, Lingyan Jiang, Mariela A. Moreno Ayala, et al.

    Detailed PK-TE-PD modeling method